Book Value per Share: Propanc Biopharma (PPCB)

Graphic logo of Propanc Biopharma, Inc. (PPCB)

Propanc Biopharma Inc (PPCB) is investing in the costly development of enzyme-based tumor treatments, anticipating high margins following patent approval. This book value per share chart confirms the capital dynamics, where the 28.60 level reflects the current value. Profit potential depends on the procurement of the therapy by clinics. The operating model relies on a lean staff of scientists and the outsourcing of all clinical trials.

PPCB: Propanc Biopharma Inc Net Asset Value per Share 08/16/2025 - 10/27/2026

Propanc Biopharma Inc. - analytical breakdowns and key metrics (PPCB)

- price and consensus price forecast:
Stock Price Propanc Biopharma, Inc.|PPCB - Consensus Target
- market capitalization data:
Market Capitalization Propanc Biopharma Inc.|PPCB - Total Company Value
- book capitalization data:
Net Assets per Single Share Propanc Biopharma|PPCB - Total Stockholders' Equity|Market Value to Book Value Ratio propanc.com|PPCB - Total Business Assets
- debt and liquidity data:
Total Debt to Capital Propanc Biopharma Inc|PPCB - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Propanc Biopharma, Inc.|PPCB - Company Cumulative Debt|Debt to Book Capitalization Ratio Propanc Biopharma Inc.
Fundamental company valuation:PPCB - propanc.com
Flagship merchandise of Propanc Biopharma, Inc.

Book value per share reflects the volume of net assets minus all liabilities, determining the intrinsic value of an investor's stake in the issuer's equity. By analyzing the accounting data on share value via the GURU.Markets platform, one can assess the financial stability of Propanc Biopharma Inc (PPCB) as it prepares for the initial phases of cancer therapy clinical trials and patent protection, allowing for the verification of resource preservation to execute its R&D strategy.

Competitor analysis for Propanc Biopharma Inc

GMAB: Book Value per Share|EXEL - Accounting Value per Share|Nuvalent, Inc. (NUVL) - Book Value per Share|KYMR (kymeratx.com) - Net Assets per Single Share|Net Assets per Single Share IDYA (IDEAYA Biosciences, Inc.)|Net Asset Value per Share ELVN|Net Assets per Single Share ORIC Pharma ORIC|Equity per Share Relay Corp (RLAY)|Nurix Therapeutics - Book Value per Share|tyra.bio - Accounting Value per Share|VSTM (Verastem) - Net Assets per Single Share|GLUE: Net Asset Value per Share|Cullinan Therapeutics Inc (CGEM) - Net Assets per Single Share|IMRX (Immuneering Corp.) - Net Assets per Single Share|Net Assets per Single Share CCCC (C4 Therapeutics, Inc.)|Net Asset Value per Share blackdiamondtherapeutics.com|RPTX: Book Value per Share|Book Value of One Share PMV Pharmaceuticals Inc. PMVP|KPTI: Accounting Value per Share|BGMS - Net Asset Value per Share|Accounting Value per Share Aadi Bio (AADI)|Aileron Therapeutics (ALRN) - Accounting Value of a Share|BPMC - Accounting Value per Share|GlycoMimetics (GLYC) - Book Price of a Share|SWTX (SpringWorks) - Book Value per Share